RESEARCH ARTICLEOpen Access
The effectiveness of individual interpersonal
psychotherapy as a treatment for major
depressive disorder in adult outpatients:
a systematic review
Madelon L J M van Hees1*, Thomas Rotter1,2, Tim Ellermann3and Silvia M A A Evers1,4
Background: This systematic review describes a comparison between several standard treatments for major
depressive disorder (MDD) in adult outpatients, with a focus on interpersonal psychotherapy (IPT).
Methods: Systematic searches of PubMed and PsycINFO studies between January 1970 and August 2012 were
performed to identify (C-)RCTs, in which MDD was a primary diagnosis in adult outpatients receiving individual IPT
as a monotherapy compared to other forms of psychotherapy and/or pharmacotherapy.
Results: 1233 patients were included in eight eligible studies, out of which 854 completed treatment in outpatient
facilities. IPT combined with nefazodone improved depressive symptoms significantly better than sole nefazodone,
while undefined pharmacotherapy combined with clinical management improved symptoms better than sole IPT.
IPT or imipramine hydrochloride with clinical management showed a better outcome than placebo with clinical
management. Depressive symptoms were reduced more in CBASP (cognitive behavioral analysis system of
psychotherapy) patients in comparison with IPT patients, while IPT reduced symptoms better than usual care and
wait list condition.
Conclusions: The differences between treatment effects are very small and often they are not significant.
Psychotherapeutic treatments such as IPT and CBT, and/or pharmacotherapy are recommended as first-line
treatments for depressed adult outpatients, without favoring one of them, although the individual preferences of
patients should be taken into consideration in choosing a treatment.
Keywords: Interpersonal psychotherapy, Major depressive disorder, Systematic review
Major depressive disorder (MDD) is a mental disorder
characterized by a depressed mood, diminished interest or
pleasure, sleeping problems and tiredness, and negative
thoughts . The mean one-year-prevalence of depression
in European inhabitants between 18 and 65 years old is
6.9% , and 16.2-16.6% of US adults develop a major
depressive disorder [3,4]. Furthermore, depression causes a
high burden worldwide, taking fourth place in a ranking of
leading contributors to the burden of diseases in 2000. In
2020, it is estimated that depression will take second place
in the ranking for all ages and sexes . Moreover, depres-
sion is the leading cause of years of life lived with disability,
in all ages and sexes, accounting for 11.9% of all disability
. Since it appears that persons suffering from mental
disorders make more use of health care services , the
increasing prevalence of depression leads to an increase in
health care costs.
Research  and Dutch guidelines  suggest treating
depression with psychotherapy
Psychotherapy follows several kinds of methodologies. For
depression, Cognitive (Behavior) Therapy (CBT) and
Interpersonal Psychotherapy (IPT) are often applied. CBT
* Correspondence: firstname.lastname@example.org
1Caphri, School of Public Health and Primary Care; Faculty of Health,
Medicine, and Life Sciences, Maastricht University, Maastricht, the
Full list of author information is available at the end of the article
© 2013 van Hees et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
van Hees et al. BMC Psychiatry 2013, 13:22
originates from behavior therapy and cognitive therapy,
and combines elements of both therapies [10-12]. IPT was
originally developed for treating acute depression by
improving the interpersonal functioning with important
others [13-17]. This study will focus on the effectiveness
and efficacy of IPT, since CBT has been subject of many
studies up until now, while IPT has only recently become
a subject of interest.
As a monotherapy for adults, individual IPT appears to
be an effective treatment for depression [18-20], and several
reviews [21-25], and meta-analyses [26-33] have been per-
formed on the effectiveness of all kinds of methodologies of
psychotherapy. Nevertheless, psychotherapy is a broad
concept, and reviews and meta-analyses have often focused
on different combinations of psychotherapy for treating
depression without comparing one specific sole treatment
to another [21,25-30,32,34]. Furthermore, although sole
individual IPTappears to be effective, few reviews focus on
sole individual IPT in adults with MDD as a primary diag-
nosis. Often, dissimilar study populations are compared
with each other, for example adult, adolescent, and elderly
patients in one study [23,25-30,33-35]. Furthermore, several
more types of depression exist: dysthymic disorder or
depression with medical conditions, for example, but this
review will focus only on MDD. Chronic MDD and post-
partum depression (PPD) will be included in this systematic
review, for the following reasons. First of all, treatment for
patients with chronic and non-chronic depression is equal
in terms of content and structure. Therefore, the treat-
ments of these patient groups are comparable. Secondly,
the symptoms of both kinds of depression are comparable
in terms of severity and content, which makes the patients
comparable. Furthermore, women with PPD experience the
same kind of symptoms as patients with MDD.
Since comorbidity is very common in patients suffering
from depression, and this possibly increases the severity of
the depression [36-44], this review will focus on MDD as a
primary diagnosis with possible comorbidity.
Other factors influencing the results of previously
executed systematic reviews include different age groups, in
which form the provided IPT is administered, distinct
settings, and the time periods during which the studies
were executed. IPT is often adjusted for applicability to
elderly  or adolescent  depressed patients, or in the
form of group IPT . Therefore, these kinds of treat-
ments may be hard to compare with each other. That is
why this review focuses on individual IPT. From here on,
when IPT is described in the review, individual IPT is
meant, unless described otherwise. Furthermore, the setting
in which treatment takes place suggests the depression’s
level of severity. It is assumed that inpatients have a more
severe depression, which is harder to treat. In addition,
inpatient care is often multidisciplinary, which makes it
difficult to examine the effects of separate therapies.
Research has been conducted on IPT since the 70s, which
is why the date limit for this review is set on 1970. This
review will give an overview of studies published between
January 1970 and August 2012, with a focus on sole IPT
administered to adults. Since some therapies have an effect
relatively quickly, we did not apply a minimum for duration
of a therapy.
With all of the above in mind, the aim of this study is to
give an overview of recent literature describing the effect-
iveness and efficacy of sole individual IPT in comparison
with standardized forms of treatment for treating patients
with MDD as a primary diagnosis. The following research
question has been formulated: Is individual interpersonal
psychotherapy more preferable in comparison with other
standardized forms of treatment for treating adult outpati-
ents with a primary diagnosis of major depressive disorder?
In order to answer this question, a systematic review will
be performed on RCTs and C-RCTs comparing the effect-
iveness (the outcome of a new treatment compared to
other kinds of treatment(s), usually in a clinical setting) or
efficacy (the outcome of treatments in homogeneous
patient groups, usually in an experimental setting)  of
individual sole IPT with other standardized forms of treat-
ment, for treating adult outpatients with MDD as a primary
This paragraph will outline which steps were taken in
order to perform this systematic review. An overview of
the methods used for data collection, study selection,
and data analysis will be provided.
RCTs about IPT for depression were collected by searching
PubMed and PsycINFO for studies published between
January 1970 and August 2012. The following medical sub-
ject heading (MeSH) categories and keywords were used:
disorder, dysthymic disorder, interpersonal psychotherapy,
treatment outcome, clinical trials. The exact search terms
and MeSH headings can be found in the additional files
(Additional file 1 – Search strategy). All titles and abstracts
were screened, and only studies which met the review
inclusion criteria (see next paragraph and Table 1) were
selected for further review. Citation tracking and snowbal-
ling techniques added studies to the second screening
phase, in which selected studies were screened for eligibility
using a predefined checklist (see Data analysis) (Additional
file 2 – Checklist).
Only studies with sufficient methodological quality meeting
the inclusion criteria were selected for this review. The
van Hees et al. BMC Psychiatry 2013, 13:22
Page 2 of 10
criteria for selection will be described shortly. An overview
of the inclusion and exclusion criteria is provided in
Studies were included if they were randomized or
cluster-randomized evaluations (RCTs or C-RCTs) pub-
lished in English after January 1st, 1970, and took place in
western jurisdictions, to ensure high internal validity.
These studies had to focus on MDD (non-chronic or
chronic) as a primary diagnosis in adults (18–65 years
old). The diagnosis must have been reached using a formal
classification system, such as the Diagnostic and Statistical
Manual of Mental Disorders (DSM) , the International
Classification of Diseases (ICD) , or the Research
Diagnostic Criteria . Bipolar disorders as primary
diagnoses were excluded, as well as cases where the
patients were elderly people or adolescents, or in cases
in which physical conditions might contribute to the
(severity of) depressive symptoms. The proposed inter-
vention must have been individual sole IPT, in comparison
with other psychotherapies, pharmacotherapy, or com-
bined treatment. Group IPTand other kinds of treatments
were excluded. Studies executed in ambulant care or
primary care were included, whereas inpatient care
patients were excluded.
By making the inclusion criteria very strict, a more homo-
geneous group, with a narrower scope, was created, which
made it possible to focus on clinical applicability of the
treatments for these kinds of patients.
Before the data were analyzed for this review, the methodo-
logical quality of the studies included after screening has
been assessed, using a predefined checklist (Additional file
2 – Checklist). This checklist was composed of Delphi-list
questions  and questions assessing the risk of bias in
effect evaluation studies . General questions were
composed for collecting relevant information about the
study, after which the resulting information was entered in
a Microsoft Excel table for a clear overview. This overview
was used to create a table of evidence of the extracted study
data, and to summarize the most important findings. MH
performed the analysis and consulted TR in case of doubt.
In this case, the analyses were double checked and consen-
sus was reached.
The literature search resulted in 3981 studies, of which
3911 were excluded from further review for several reasons,
documented below. Figure 1 shows the flow diagram of
included and excluded studies. Studies were excluded when
they did not meet the inclusion criteria, based on the title
and abstract: i.e. they did not focus on MDD as a primary
diagnosis, on individual sole IPT, or the target group was
anything other than adults. Another 62 were excluded after
reading the full text, leaving 8 articles eligible for this
These 62 full-text articles were excluded for the follow-
ing reasons: being reviews or meta-analyses [21-23,25-
30,32,34,53-60], being a protocol for a study , being a
study based on earlier/other studies [43,45,62-76], there
was no comparison in the study , MDD was not the
primary diagnosis [78-82], the study had the wrong aim
for this review [83-86], there was no research data [87-91],
or one of the interventions was not IPT as described in
the eligibility criteria [35,92-100]. See Additional file 3 –
List of excluded studies for a detailed description of the
reasons for exclusion.
Description of the studies
The main characteristics of the RCT studies included are
summarized in Table 2. One study was carried out in the
Netherlands , one in New Zealand , one in
Table 1 Summary of inclusion and exclusion criteria
Inclusion criteriaExclusion criteria
Type of study
Randomized controlled trial
English languageOther languages
Adults (18–65) Elderly people or adolescents
Major depressive disorder as a primary diagnosisBipolar disorder
Individual sole IPT Group IPT
IPT combined with other therapy
Other evidence-based psychotherapies, combined treatment,
Alternative therapy, bibliotherapy, complementary therapy,
counseling, psychoeducation, supportive therapy
Outpatient ambulant care, primary careInpatient care
Western jurisdictionsOutside of Western jurisdictions
IPT Interpersonal Psychotherapy.
van Hees et al. BMC Psychiatry 2013, 13:22
Page 3 of 10
Canada , one in the UK , one in Germany ,
and three in the USA [106-108]. All studies clearly
described eligibility criteria and success-of-treatment point.
All but two [103,104] included an intention-to-treat ana-
lysis. Seven studies reported comparable sociodemographic
and psychiatric variables at baseline. One  did not re-
port these variables.
A total of 1233 patients were included in the review,
of whom 854 completed treatment in outpatient facil-
ities. Of the patients included, 392 received IPT, 14
received CBASP (Cognitive Behavioral Analysis System
of Psychotherapy), 160 received CBT, 153 received
pharmacotherapy (nefazodone, nortriptyline hydrochlor-
ide, or venlafaxine hydrochloride), 67 received pharma-
cotherapy plus clinical management, 49 received IPT
and nefazodone, 47 received IPT and a placebo, 34
received a placebo plus clinical management, 92 received
usual care consisting of communication with a physician
for appropriate treatment, and 51 were put on a wait list.
The mean age in seven studies [101,102,104-106] ranged
from 29.4 to 40.2 years old, and the percentage of female
patients varied from 55% to 83%, except for one study,
in which only females participated . One study did
not report these data . All patients were diagnosed
with non-psychotic MDD as a primary diagnosis
according to the DSM-III-R , DSM-IV , or the
Research Diagnostic Criteria .
IPT in all studies was based on a standardized manual
[14,17], as was CBASP  and CBT [12,112,113]. The
number of IPT and CBT sessions varied from 8 to 24 in
a 12- or 16-week period, and most of the sessions were
held weekly. Physicians administering nefazodone or
nortriptyline were instructed to follow a manual.
Patients receiving nefazodone started at 100 mg capsules
per day, and doses were gradually increased to a mini-
mum of 400 mg, with a maximum of 600 mg .
Patients receiving nortriptyline started at 25 mg per day,
aiming for blood levels of 190–570 nmol/liter .
Patients receiving imipramine hydrochloride had a
dosage between 150 and 185 mg. Pharmacotherapists
administering venlafaxine followed an evidence-based
protocol of 37.5 mg twice-daily doses . Pharmaco-
therapy plus clinical management was administered by
a psychiatrist who followed the client for the duration
of the protocol associated with the antidepressant medi-
cation , or as long as the clinical management
would be administered .
Risk of bias
Risk of bias was measured and summarized (see Figure 2)
according to the standards of the Cochrane Collaboration
. Although this was not always described exhaustively,
all studies used randomization and seemed to present
complete outcome data. Therefore, all included studies had
a low risk of selection bias and attrition bias. Nevertheless,
two studies [103,107] had an unclear risk of detection bias
and one of them  had a high risk of reporting bias.
Another study  had a high risk of detection bias. Not-
withstanding these higher levels of bias, these studies have
been included in this review.
Findings on outcome measurements
The outcome of the HAMD showed an overall decrease in
the level of depression over time (p<0.001) between the
four treatment conditions (IPT, nefazodone, IPT and nefa-
zodone, IPT and placebo), but this was not statistically sig-
nificant. A significant difference was found between IPT
and nefazodone and the use of nefazodone without IPT in
favor of the first (for the intent to treat sample: adjusted
OR (95% CI)=3.22 (1.02-10.12), p=0.045). Furthermore, a
significant difference was found in the MADRS scores.
Patients receiving IPT with nefazodone improved more
than did patients receiving nefazodone without IPT. Fur-
thermore, the nefazodone condition showed only a small
improvement after the first six weeks .
management (CM) was significantly superior to placebo
with CM on general level of functioning. Patients receiving
IPT or imipramine hydrochloride with CM appeared to
combined with clinical
Figure 1 Flow diagram of included and excluded articles;
reasons in Additional file 3.
van Hees et al. BMC Psychiatry 2013, 13:22
Page 4 of 10
have a better outcome on the HRSD than patients receiving
placebo with CM (p=0.018 and p=0.017). Furthermore,
these patients showed a significantly higher percentage in
the recovery analysis compared to placebo with CM
patients, measured by a score of six or lower on the HRSD
(p=0.010 and p=0.013) .
In the Luty et al. study , depressive symptoms
improved for about 55%. No statistically significant differ-
ences were found between IPT and CBT on the primary
outcome measure MADRS (9.5% mean difference (95%
CI), p=0.059), nor after controlling for baseline severity
HRSD scores were significantly higher in the IPT con-
dition compared to the PHT-CM condition (t(96)=−2.46,
p<0.05, d=−0.50). No significant differences were found
between IPT and CBT conditions (t(96)=−1.19, p=0.46,
d=−0.24), or between CBT and PHT-CM conditions
(t(96)=−1.35, p=0.37, d=−0.28) .
Depressive symptoms, measured by the HAMD and
BDI, improved significantly (p<0.001) in the first six
weeks for patients receiving IPT or venlafaxine .
Although the venlafaxine group showed a slightly better
outcome than the IPT group, no significant differences
were found after six weeks.
Table 2 Summary of the characteristics of the includes studies
Study N included N completed
pre- and post-
Blom et al.
193 132Adults with MDD IPT vs.Nefazodone vs.IPT
16HAMD 12 weeks
Elkin et al.
250 155 Adults with MDD IPT vs. CBT vs. IMI-CM vs.
16HRSD 16 weeks
Luty et al.
177 159 Adults with MDDIPT vs.CBT 16MADRS16 weeks
159 102Adults with MDD IPT vs.CBT vs.PHT-CM16 HRSD 16 weeks
28 28 Adults with MDDIPT vs.Venlafaxine 16HAMD6 weeks
12099Women with PPD IPT vs. WLC12 HRSD 12 weeks
30 29 Adults with early
IPT vs.CBASP16 with
276150Adults with MDDIPT vs.Nortriptyline vs.
CBASP Cognitive Behavioral Analysis System of Psychotherapy; CBT Cognitive Behavior Therapy; HAMD Hamilton Depression Rating Scale; HRSD Hamilton Rating
Scale Depression; IMI-CM imipramine plus clinical management; IPT Interpersonal Psychotherapy; MADRS Montgomery-Åsberg Depression Rating Scale; MDD Major
Depressive Disorder; PHT-CM pharmacotherapy plus clinical management; PLA-CM placebo plus clinical management; WLC wait list condition.
Figure 2 Summary of risk of bias in six studies.
van Hees et al. BMC Psychiatry 2013, 13:22
Page 5 of 10
O’Hara described recovery rates for women with PPD
based on HRSD scores and BDI scores, favoring IPT over
wait list condition (WLC). Based on HRSD scores
(HRSD ≤6), IPT had a recovery rate of 31.7%, compared to
15% of WLC (p=0.03). Based on BDI scores (BDI ≤9), IPT
had a recovery rate of 38.3%, while women in the WLC
group showed a recovery rate of 18.3% (p=0.02) .
In both the IPT and CBASP group , HRSD scores
decreased after 16 weeks, but only in the CBASP group
p=0.004). BDI scores were significantly lower after
16 weeks in both groups (IPT: t(14)=2.34, p=0.034;
CBASP: t(13)=5.01, p<0.001). HRSD scores did not show a
significant difference between the groups, whereas BDI
scores showed a significantly higher reduction in depressive
symptoms in the CBASP group after 16 weeks (mean BDI
score of 10.79 vs. 21.27 in IPT; F(1,26)=4.34, p=0.047, treat-
ment effect size: Cohen’s d=0.87).
Eight months after the start of the treatments (IPT,
nortriptyline, or usual care), all HRSD scores improved
significantly (χ2=816.14, df=6, p<0.001), and a significant
difference was found between the groups (χ2=14.92,
df=2, p=0.001). Post-hoc group t-test comparisons
showed significant differences (p<0.01) in HRSD scores
between nortriptyline and usual care, at most measure-
ment times favoring nortriptyline, and between IPT and
usual care, favoring IPT after eight months. No signifi-
cant difference was found between IPT and nortriptyline
at any moment in time .
Meta-analysis and summary of findings
As can be seen in Table 2, heterogeneity between the
studies exists, which made it difficult to make meta-
analytic comparisons. However, three studies were com-
parable in terms of measuring the effects of IPT and
CBT [102,103,107]. The mean difference between the
treatments was 1.01 (95% CI: -0.34, 2.37) favoring CBT
over IPT, but did not reach a statistically significant
level. See Figure 3 for more detailed information.
Although no further meta-analyses were possible, and
results appeared to be inconsistent, some conclusions
can be drawn from these studies. IPT combined with
nefazodone improved MADRS scores significantly better
than did nefazodone alone . Furthermore, higher
HRSD scores were found in IPT patients in comparison
with PHT-CM patients . IPT patients showed a sig-
nificantly greater decrease of HRSD and BDI scores than
WLC patients . As measured with the BDI, depres-
sive symptoms were reduced more in CBASP patients in
comparison with IPT patients . Finally, IPT patients
produced lower HRSD scores in comparison with
patients receiving usual care .
The results of this systematic review show inconsistent
findings in the eight heterogeneous studies included.
The effectiveness and efficacy of the several treatments
is comparable in most studies, and some conclusions
may be drawn. Overall, the efficacy of IPT and CBT
appears to be equal . Contradictory results were
found in IPT in comparison with pharmacotherapy. IPT
combined with nefazodone appears to have a higher effi-
cacy than sole nefazodone , while pharmacotherapy
combined with clinical management appears to have a
higher efficacy than IPT alone . However, another
study showed comparable results between IPT and im-
ipramine hydrochloride with clinical management (CM),
which both returned a better outcome on the HRSD
compared to placebo with CM . Furthermore, ven-
lafaxine seems to reduce depressive symptoms more
than IPT after six weeks, although this outcome was not
significant . The effects of using sole IPT and sole
nortriptyline do not significantly differ from each other
. IPT and CBASP appear to be very comparable in
efficacy, although scores of the BDI showed a slight pre-
ference for CBASP . Finally, IPT appears to be
more effective than wait list condition , and usual
care after eight months, as does nortriptyline .
These outcomes suggest that several kinds of treat-
ments are effective or efficacious for depressed patients,
although one has to keep in mind the small number of
Figure 3 Comparison of HRSD scores between IPT and CBT. CBT Cognitive Behavior Therapy; IPT Interpersonal Psychotherapy; SD Standard
van Hees et al. BMC Psychiatry 2013, 13:22
Page 6 of 10
included studies. Patients are recommended to choose a
treatment which fits their personal preferences, since
this may affect the outcome of the treatment. Policy
makers are advised to base regulations on the effective-
ness and efficacy of treatments in general, instead of a
slightly different effect between one treatment and the
other, since these studies do not take individual differ-
ences and preferences into account.
This review has a number of limitations. First, this
review included only adult outpatients with unipolar,
non-psychotic major depression as a primary diagnosis.
Although these inclusion criteria were a deliberate choice,
this review has consequences for the generalizability. These
results are not generalizable to children, adolescents, or the
elderly, to patients with other kinds of depression, or to
patients suffering from a combination of depression and
medical conditions, or from depression and substance
abuse. Furthermore, no distinction has been made in the
severity of depression, which causes a higher heterogeneity
in the complete sample, making results more uncertain.
Second, only eight studies with a limited number of parti-
cipants were included in this review. Although most studies
showed a low risk of bias, the small size of the sample may
increase this risk. Furthermore, results are harder to
generalize with a small number of participants, especially
because many different kinds of treatments have been com-
pared with each other (high heterogeneity), which limited
the number of participants in the groups not receiving IPT.
Moreover, the limited number of included studies in this
review, makes one question the applicability of the
Cochrane guidelines for conducting a systematic review
, for clinical treatments in mental health care.
Third, all included patients were outpatients and there-
fore had to be willing and motivated to participate in the
selected studies. This may cause some bias, since not all
types of patients could be included in the studies. For
example, treatment-resistant depressed patients may have
been less motivated than patients who were not treatment-
resistant, and it may not be possible to generalize results
for these patients.
Fourth, pharmacotherapy consisted of different types of
antidepressant medication. Although these medications
may seem to be equally effective, some differences may
exist, which may interfere with the results of this review.
Furthermore, one study  used nefazodone as pharma-
cotherapy, although this medication has been withdrawn
in, amongst other countries, the USA and the Netherlands,
because of hepatotoxicity associated with this drug .
Fifth, some of the findings were based on the scores of
the HRSD [101,103-108]. However, this scale has re-
cently been criticized for having multiple problems, in-
cluding among others the existence of different versions
and not being as sensitive as other scales [115,116].
Despite these flaws, the HRSD has been used in many
studies and the outcomes of this scale can therefore not
be excluded from this review. Furthermore, findings were
also based on the MADRS [101,102], which is more sensi-
tive to treatment effect than the HAMD , and on the
BDI [104,105] which correlates weakly with the HDRS
 and has several advantages and disadvantages ,
but is widely used.
Sixth, one study  measured the efficacy only after six
weeks, without follow-up measurement. This is a very short
period for measuring the efficacy of IPT. Therefore, the
results of this study may be questionable. Furthermore,
these authors did not include an intention-to-treat analysis,
which increases the risk of bias.
Finally, although a profound search has been performed,
there is no complete certainty that all studies eligible for
this review have been found. Furthermore, the search was
directed only at published studies, automatically excluding
unpublished data, causing possible publication bias.
It can be concluded that the differences between the
effects and efficacy of several types of treatment are very
small and they are often not significant. This in turn is
consistent with a study concluding that the effects of
psychotherapy for adult depression in meta-analyses are
overestimated . Nevertheless, usual care, as described
in the study of Schulberg et al. , appears to be inef-
fective and is not recommended as a treatment for MDD.
Therefore, psychotherapeutic treatments such as IPT and
CBT, and/or pharmacotherapy are recommended as first-
line treatments for depressed adult outpatients. This
conclusion is consistent with a previous study , and
review , and previous meta-analyses [28,29,32,33,55],
although, as has been stated in the introduction, these
studies had several limitations as well. Furthermore, it is
recommended that the type of treatment is adjusted to the
individual preferences of the patient.
Future research should focus on a larger sample includ-
ing patients with MDD, while correcting for severity of de-
pression. Since many studies focused on IPT combined
with medication, it is recommended that these studies be
included in future research as well. Furthermore, it is
recommended that future studies included in a review,
have longer follow-up periods. All studies should aim for
the highest quality standards currently set.
Additional file 1: Search strategy.
Additional file 2: Checklist.
Additional file 3: List of excluded studies.
van Hees et al. BMC Psychiatry 2013, 13:22
Page 7 of 10
The authors declare that they have no competing interests.
MH designed the study with the support of SE and TR. MH undertook the
literature search with help from TE, identified potential and final selected
articles, interpreted results, drafted and revised all versions of the manuscript,
supported by SE and TR. In case of doubt during the screening and
analyzing phase, TR was consulted. SE and TR supervised the development
of the manuscript. All authors read and approved the final version.
This study was not funded by any grants. We thank Tim Ellermann and
Henrietta Hazen for help during the development of an adequate search
strategy. MH also thanks SE and TR for their support.
1Caphri, School of Public Health and Primary Care; Faculty of Health,
Medicine, and Life Sciences, Maastricht University, Maastricht, the
Netherlands.2College of Pharmacy and Nutrition, University of Saskatchewan,
Saskoon, Canada.3Institute for Public Health and Nursing Research (IPP),
University of Bremen, Bremen, Germany.4Caphri, School of Public Health and
Primary Care; Department of Health Services Research, Maastricht University,
Maastricht, the Netherlands.
Received: 9 December 2011 Accepted: 7 January 2013
Published: 11 January 2013
1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, Text Revised. Washington DC: American Psychiatric
2. Wittchen HU, Jacobi F: Size and burden of mental disorders in Europe - a
critical review and appraisal of 27 studies. Eur Neuropsychopharmacol
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ,
Walters EE, Wang PS: The epidemiology of major depressive disorder.
Results from the national comorbidity survey replication (NCS-R). J Am
Med Assoc 2003, 289:3095–3105.
4. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime
prevalence and age-of-onset distributions of DSM-IV disorders in the
national comorbidity survey replication. Arch Gen Psychiatry 2005,
6. World Health Organization: The World health report: 2001: Mental health: new
understanding, new hope. 2001.
7.Kessler RC, Demler O, Frank RG, Olfsen M, Pincus HA, Walters EE, Wang P,
Wells KB, Zaslavsky AM: US prevalence and treatment of mental disorders:
1990–2003. N Engl J Med 2005, 352(24):2515–2523.
8. Weihs K, Wert JM: A primary care focus on the treatment of patients with
major depressive disorder. Am J Med Sci 2011, XXX:XXX.
Depressie (eerste revisie). Richtlijn voor de diagnostiek, behandeling en
begeleiding van volwassen patiënten met een depressieve stoornis.
10. Boelens W: Protocollaire behandeling van depressieve patiënten:
cognitieve gedragstherapie. In Protocollaire behandelingen in de ambulante
geestelijke gezondheidszorg, deel I. Edited by Keijsers GPJ, Minnen A,
Hoogduin CAL. Houten: Bohn Stafleu Van Loghum; 2004:154–182.
11. Lewinsohn PM: The behavioral study and treatment of depression. In
Progress in behavior modification, volume 1. Edited by Hersen M, Eisler RM,
Miller PM. New York: Academic Press; 1975.
12. Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive Therapy of Depression. New
York: Guilford; 1979.
13. Blom MBJ, Jonker K: Protocollaire behandeling van depressieve patiënten:
interpersoonlijke psychotherapie. In Protocollaire behandelingen in de
ambulante geestelijke gezondheidszorg, deel II. Edited by Keijsers GPJ, Minnen
A, Hoogduin CAL. Houten: Bohn Stafleu Van Loghum; 2004:96–116.
14. Klerman GL, Weismann MM, Rounsaville BJ, Chevron ES: Interpersonal
Psychotherapy of Depression. New York: Basic Books; 1984.
15.Klerman GL, Weissman MM: New applications of interpersonal psychotherapy.
Washington, DC: American Psychiatric Press; 1994.
Jonker K, Blom M: Interpersoonlijke psychotherapie. In Depressie: theorie,
diagnostiek en behandeling. Edited by Albersnagel FA, Emmelkamp PMG,
Van den Hoofdakker RH. Houten/Diegem: Bohn Stafleu Van Loghum;
Weissman MM, Markowitz JC, Klerman GL: Comprehensive guide to
interpersonal psychotherapy. New York: Basic Books; 2000.
DiMascio A, Weissman MM, Prusoff BA, Neu C, Zwilling M, Klerman GL:
Differential symptom reduction by drugs and psychotherapy in acute
depression. Arch Gen Psychiatry 1979, 36:1450–1456.
Weissman MM, Prusoff BA, DiMascio A, Neu C, Goklaney M, Klerman GL:
The efficacy of drugs and psychotherapy in the treatment of acute
depressive episodes. Am J Psychiatry 1979, 136:555–558.
Reynolds CF, Frank E, Perel JM, Imber SD, Cornes C, Morycz RK, Mazumdar S,
Miller MD, Pollock BG, Hind Rufai A, et al: Combined pharmacotherapy and
psychotherapy in the acute and continuation treatment of elderly
patients with recurrent major depression: a prelimenary report. Am J
Psychiatry 1992, 149:1687–1692.
Cascalenda N, Perry JC, Looper K: Remission in major depressive disorder:
a comparison of pharmacotherapy, psychotherapy, and control
conditions. Am J Psychiatry 2002, 159:1354–1360.
De Mello MF, De Jesus Mari J, Bacaltchuk J, Verdeli H, Neugebauer R:
A systematic review of research findings of the efficacy of interpersonal
therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 2005,
Hollon SD, Ponniah K: A review of empirically supported psychological
therapies for mood disorders in adults. Depress Anxiety 2010, 27:891–932.
Parker G, Parker I, Brotchie H, Stuart S: Interpersonal psychotherapy for
depression? The need to define its ecological niche. J Affect Disord 2006,
Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C: Combined
pharmacotherapy and psychological treatment for depression.
A systematic review. Arch Gen Psychiatry 2004, 61:714–719.
Cuijpers P, Dekker J, Hollon SD, Andersson G: Adding psychotherapy to
pharmacotherapy in the treatment of depressive disorders in adults:
a meta-analysis. J Clin Psychiatry 2009, 70:1219–1229.
Cuijpers P, Van Straten A, Bohlmeijer E, Hollon SD, Andersson G: The effects
of psychotherapy for adult depression are overestimated: a meta-
analysis of study quality and effect size. Psychol Med 2010, 40:211–223.
Cuijpers P, Van Straten A, Hollon SD, Andersson G: The contribution of
active medication to combined treatments of psychotherapy and
pharmacotherapy for adult depression: a meta-analysis. Acta Psychiatr
Scand 2010, 121:415–423.
Cuijpers P, Van Straten A, Van Oppen P, Andersson G: Are psychological
and pharmacologic interventions equally effective in the treatment of
adult depressive disorders? A meta-analysis of comparative studies.
J Clin Psychiatry 2008, 69:1675–1685.
Cuijpers P, Van Straten A, Van Schaik A, Andersson G: Psychological
treatment of depression in primary care: a meta-analysis. Br J Gen Pract
Gloaguen V, Cottraux J, Cucherat M, Blackburn IM: A meta-analysis of the
effects of cognitive therapy in depressed patients. J Affect Disord 1998,
Guidi J, Fava GA, Fava M, Papakostas GI: Efficacy of the sequential
integration of psychotherapy and pharmacotherapy in major depressive
disorder: a preliminary meta-analysis. Psychol Med 2011, 41:321–331.
Cuijpers P, Geraedts AS, Van Oppen P, Andersson G, Markowitz JC, Van
Straten A: Interpersonal psychotherapy for depression: a meta-analysis.
Am J Psychiatry 2011, 168:581–592.
Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K,
Grochocinski V, Kupfer DJ: Treatment of major depression with
psychotherapy or psychotherapy-pharmacotherapy combinations. Arch
Gen Psychiatry 1997, 54:1009–1015.
De Mello MF, Myczcowisk LM, Menezes PR: A randomized controlled trial
comparing moclobemide and moclobemide plus interpersonal
psychotherapy in the treatment of dysthymic disorder. J Psychother Pract
Res 2001, 10:117–123.
Kroenke K, Shen J, Oxman TE, Williams JW Jr, Dietrich AJ: Impact of pain on
the outcomes of depression treatment: results from the RESPECT trial.
Pain 2008, 134:209–215.
van Hees et al. BMC Psychiatry 2013, 13:22
Page 8 of 10
37.Poleshuck EL, Bair MJ, Kroenke K, Watts A, Tu X, Giles DE: Pain and
depression in gynecology patients. Psychosomatics 2009, 50:270–276.
Poleshuck EL, Talbot NL, Su H, Tu X, Chaudron L, Gamble S, Giles DE: Pain
as a predictor of depression treatment outcomes in women with
childhood sexual abuse. Compr Psychiatry 2009, 50:215–220.
Karp JF, Scott J, Houck P, Reynolds CF III, Kupfer DJ, Frank E: Pain predicts
longer time to remission during treatment of recurrent depression. J Clin
Psychiatry 2005, 66:591–597.
Yates WR, Mitchell J, Rush J, Trivedi MH, Wisniewski SR, Warden D, Hauger
RB, Fava M, Gaynes BN, Husain MM, et al: Clinical features of depressed
outpatients with and without co-occurring general medical conditions in
STAR*D. Gen Hosp Psychiatry 2004, 26:421–429.
Ferrando SJ, Freyberg Z: Treatment of depression in HIV positive
individuals: a critical review. Int Rev Psychiatry 2008, 20:61–71.
Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY,
Pollock BG, Stack J, Miller MD, Reynolds CF: Effect of comorbid anxiety on
treatment response and relapse risk in late-life depression: controlled
study. Br J Psychiatry 2007, 190:344–349.
Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR: Treatment
outcomes for primary care patients with major depression and lifetime
anxiety disorders. Am J Psychiatry 1996, 153:1293–1300.
Young JF, Mufson L, Davies M: Impact of comorbid anxiety in an
effectiveness study of interpersonal psychotherapy for depressed
adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45:904–912.
Reynolds CF, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S, Houck PR:
Treatment outcome in recurrent major depression: a post hoc
comparison of elderly ("young old") and midlife patients. Am J Psychiatry
Mufson L, Moreau D, Weissman MM, Klerman GL: Interpersonal Therapy for
Depressed Adolescents. New York: Guilford Press; 1993.
Levkovitz Y, Shahar G, Native G, Hirsfeld E, Treves I, Krieger I, Fennig S:
Group interpersonal psychotherapy for patients with major depression
disorder - pilot study. J Affect Disord 2000, 60:191–195.
Lutz W: Efficacy, Effectiveness, and Expected Treatment. Respnse in
Psychotherapy. J Clin Psychol 2003, 59:745–750.
World Health Organization: International Statistical Classification of Diseases,
10th Revision (ICD-10). Geneva: World Health Organization; 1992.
Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria: rationale and
reliability. Arch Gen Psychiatry 1978, 35:773–782.
Verhagen AP, De Vet HCW, De Bie RA, Kessels AGH, Boers M, Bouter LM,
Knipschild PG: The Delphi-List: a criteria list for quality assessment of
randomized controlled trials for conducting systematic reviews
developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235–1241.
Higgins JPT, Green S (Eds): Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration; 2011. Available from www.cochrane-handbook.org.
Weissman MM: Recent non-medication trials of interpersonal
psychotherapy for depression. Int J Neuropsychopharmacol 2007,
Jakobsen JC, Hansen JL, Simonsen E, Gluud C: The effect of adding
psychodynamic therapy to antidepressants in patients with major
depressive disorder. A systematic review of randomized clinical trials
with meta-analyses and trial sequential analyses. J Affect Disord 2011,
De Maat SM, Dekker J, Schoevers RA, De Jonghe F: Relative efficacy of
psychotherapy and combined therapy in the treatment of depression: a
meta-analysis. Eur Psychiatry 2007, 22:1–8.
Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ:
Psychotherapy and medication in the treatment of adult and geriatric
depression: which monotherapy or combined treatment? J Clin Psychiatry
Dorrepaal E, Van Nieuwenhuizen C, Schene A, De Haan R: De effectiviteit
van cognitieve en interpersoonlijke therapie bij depressiebehandeling:
een meta-analyse. Tijdschr Psychiatr 1998, 40:27–39.
Kotova E: A meta-analysis of Interpersonal Psychotherapy, Dissertation
Abstracts International: Section B. Sciences and Engineering 2005,
Cuijpers P, Andersson G, Donker T, van Straten A: Psychological treatment
of depression: results of a series of meta-analyses. Nord J Psychiatry 2011,
60.Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD,
Andersson G: Psychotherapy for chronic major depression and
dysthymia: A meta-analysis. Clin Psychol Rev 2010, 30(1):51–62.
Kriston L, Von Wolff A, Hölzel L: Effectiveness of psychotherapeutic,
pharmacological, and combined treatments for chronic depression:
a systematic review (METACHRON). BMC Psychiatry 2010, 10:95.
Blom MBJ, Spinhoven P, Hoffman T, Jonker K, Hoencamp E, Haffmans PMJ,
Van Dyck R: Severity and duration of depression, not personality factors,
predict short term outcome in the treatment of major depression.
J Affect Disord 2007, 104:119–126.
Coulehan JL, Schulberg HC, Block MR, Madonia MJ, Rodriguez E: Treating
depressed primary care patients improves their physical, mental, and
social functioning. Arch Intern Med 1997, 157:1113–1120.
Watkins JT, Leber WR, Imber SD, Collins JF, Elkin I, Pilkonis PA, Sotsky SM,
Shea MT, Glass DR: Temporal course of change of depression. J Consult
Clin Psychol 1993, 61:858–864.
Ablon JS, Jones EE: Validity of controlled clinical trials of psychotherapy:
findings from the NIMH treatment of depression collaborative research
program. Am J Psychiatry 2002, 159:775–783.
Agosti V, Ocepek-Welikson K: The efficacy of imipramine and
psychotherapy in early-onset chronic depression: a reanalysis of the
National Institute of Mental Health Treatment of Depression
Collaborative Research Program. J Affect Disord 1997, 43:181–186.
Barber JP, Muenz LR: The role of avoidance and obsessiveness in
matching patients to cognitive and interpersonal psychotherapy:
empirical findings from the Treatment for Depression Collaborative
Research Program. J Consult Clin Psychol 1996, 64:951–958.
Blom MBJ, Hoek HW, Spinhoven P, Hoencamp E, Haffmans PMJ, Van Dyck R:
Treatment of depression in patients from ethnic minority groups in the
Netherlands. Transcult Psychiatry 2010, 47:473–490.
Brown C, Schulberg HC, Sacco D, Perel JM, Houck PR: Effectiveness of
treatments for major depression in primary medical care practice: a post
hoc analysis of outcomes for African American and white patients.
J Affect Disord 1999, 53:185–192.
Carter JD, Luty SE, McKenzie JM, Mulder RT, Frampton CM, Joyce PR: Patient
predictors of response to cognitive behaviour therapy and interpersonal
psychotherapy in a randomised clinical trial for depression. J Affect Disord
Elkin I, Gibbons RD, Shea MT, Sotsky SM, Watkins JT, Pilkonis PA, Hedeker D:
Initial severity and differential treatment outcome in the National
Institute of Mental Health Treatment of Depression Collaborative
Research Program. J Consult Clin Psychol 1995, 63:841–847.
Imber SD, Pilkonis PA, Sotsky SM, Elkin I, Watkins JT, Collins JF, Shea MT,
Leber WR, Glass DR: Mode-specific effects among three treatments for
depression. J Consult Clin Psychol 1990, 58:352–359.
Lave JR, Frank RG, Schulberg HC, Kamlet MS: Cost-effectiveness of
treatments for major depression in primary care practice. Arch Gen
Psychiatry 1998, 55:645–651.
Kim DM: Therapist effects and treatment effects in psychotherapy: Analysis on
the National Institute of Mental Health Treatment of Depression Collaborative
Research Program (NIMH TDCRP). Wisconsin: ProQuest Information &
Learning, Dissertation Abstracts International: Section B: The Sciences and
Shea MT, Elkin I, Imber SD, Sotsky SM, Watkins JT, Collins JF, Pilkonis PA,
Beckham E, Glass DR, Dolan RT, et al: Course of depressive symptoms over
follow-up. Findings from the National Institute of Mental Health
Treatment of Depression Collaborative Research Program. Arch Gen
Psychiatry 1992, 49(10):782–787.
Segal ZV, Whitney DK, Lam RW, Group CDW: Clinical guidelines for the
treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry
2001, 46(Suppl 1):29S–37S.
Blom MBJ, Hoencamp E, Zwaan T: Interpersoonlijke psychotherapie voor
depressie. Een pilot-onderzoek. Tijdschr Psychiatr 1996, 38:398–402.
Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M: A comparative
trial of psychotherapy and pharmacotherapy for "pure" dysthymic
patients. J Affect Disord 2005, 89:167–175.
Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, Bell B, Mills M,
Chalklin L, Wallik D, et al: Sertraline and/or interpersonal psychotherapy
for patients with dysthymic disorder in primary care: 6-month
comparison with longitudinal 2-year follow-up of effectiveness and
costs. J Affect Disord 2002, 68:317–330.
van Hees et al. BMC Psychiatry 2013, 13:22
Page 9 of 10
80.Markowitz JC: Psychotherapy of dysthymia. Am J Psychiatry 1994, 151 Download full-text
Markowitz JC: Psychotherapy for dysthymic disorder. Psychiatr Clin North
Am 1996, 19(1):133–149.
Svanborg C, Wistedt AA, Svanborg P: Long-term outcome of patients with
dysthymia and panic disorder: a naturalistic 9-year follow-up study.
Nord J Psychiatry 2008, 62(1):17–24.
Schulberg HC, Madonia MJ, Block MR, Coulehan JL, Scott CP, Rodriguez E,
Black A: Major depression in primary care practice. Clinical characteristics
and treatment implications. Psychosomatics 1995, 36:129–137.
Bulmash E, Harkness KL, Stewart JG, Bagby RM: Personality, stressful life
events, and treatment response in major depression. J Consult Clin
Psychol 2009, 77:1067–1077.
Kushner SC, Quilty LC, McBride C, Bagby RM: A comparison of depressed
patients in randomized versus nonrandomized trials of antidepressant
medication and psychotherapy. Depress Anxiety 2009, 26:666–673.
Frank E, Grochocinski VJ, Spanier CA, Buysse DJ, Cherry CR, Houck PR, Stapf
DM, Kupfer DJ: Interpersonal psychotherapy and antidepressant
medication: Evaluation of a sequential treatment strategy in women
with recurrent major depression. J Clin Psychiatry 2000, 61(1):51–57.
Cuijpers P, Van Straten A, Warmerdam L, Andersson G: Psychological
treatment of depression: a meta-analytic database of randomized
studies. BMC Psychiatry 2008, 8:36.
Dunner DL: Acute and maintenance treatment of chronic depression.
J Clin Psychiatry 2001, 62:10–16.
Blanco C, Lipsitz J, Caligor E: Treatment of chronic depression with a 12-
week program of interpersonal psychotherapy. Am J Psychiatry 2001,
Miller IW, Keitner GI: Combined medication and psychotherapy in the
treatment of chronic mood disorders. Psychiatr Clin North Am 1996,
Reinceke MA, Ewell Foster CJ, Rogers GM, Weill R: Medication or
psychotherapy for severe depression. Am J Psychiatry 2000,
Frank E, Kupfer DJ, Perel JM, Cornes C, Jarret DB, Mallinger AG, Thase ME,
McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance
therapies in recurrent depression. Arch Gen Psychiatry 1990, 47:1093–1099.
Bressi C, Porcellana M, Marinaccio PM, Nocito EP, Magri L: Short-term
psychodynamic psychotherapy versus treatment as usual for depressive
and anxiety disorders: a randomized clinical trial of efficacy. J Nerv Ment
Dis 2010, 198(9):647–652.
Croghan TW, Melfi CA, Dobrez DG, Kniesner TJ: Effect of mental health
specialty care on antidepressant length of therapy. Med Care 1999,
37(4 Suppl Lilly):AS20–AS23.
Cuijpers P, Van Lier PA, Van Straten A, Donker M: Examining differential
effects of psychological treatment of depressive disorder: an application
of trajectory analyses. J Affect Disord 2005, 89(1–3):137–146.
Godfrin KA, Van Heeringen C: The effects of mindfulness-based cognitive
therapy on recurrence of depressive episodes, mental health and quality
of life: A randomized controlled study. Behav Res Ther 2010, 48(8):738–746.
Kingston T, Dooley B, Bates A, Lawlor E, Malone K: Mindfulness-based
cognitive therapy for residual depressive symptoms. Psychol Psychother
2007, 80(Pt 2):193–203.
Schene AH, Koeter MW, Kikkert MJ, Swinkels JA, McCrone P: Adjuvant
occupational therapy for work-related major depression works:
randomized trial including economic evaluation. Psychol Med 2007,
Schulberg HC, Block MR, Madonia MJ, Scott CP, Lave JR, Rodriguez E,
Coulehan JL: The 'usual care' of major depression in primary care
practice. Arch Fam Med 1997, 6(4):334–339.
100. Van Roijen LH, Van Straten A, Al M, Rutten F, Donker M: Cost-utility of brief
psychological treatment for depression and anxiety. Br J Psychiatry 2006,
101. Blom MBJ, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J,
Van Dyck R: Combination treatment for acute depression is superior only
when psychotherapy is added to medication. Psychother Psychosom 2007,
102. Luty SE, Carter JD, McKenzie JM, Rae AM, Frampton CMA, Mulder RT, Joyce
PR: Randomised controlled trial of interpersonal psychotherapy and
cognitive-behavioural therapy for depression. Br J Psychiatry 2009,
103. Marshall MB, Zuroff DC, McBride C, Bagby RM: Self-criticism predicts
differential response to treatment for major depression. J Clin Psychol
104. Martin SD, Martin E, Rai S, Richardson MA, Royall R: Brain blood flow
changes in depressed patients treated with interpersonal psychotherapy
or venlafaxine hydrochloride. Arch Gen Psychiatry 2001, 58:641–648.
105. Schramm E, Zobel I, Dykierek P, Kech S, Brakemeier E, Külz A, Berger M:
Cognitive behavioral analysis system of psychotherapy versus
interpersonal psychotherapy for early-onset chronic depression: a
randomized pilot study. J Affect Disord 2011, 129:109–116.
106. Schulberg HC, Block MR, Madonia MJ, Scott CP, Rodriguez E, Imber SD, Perel
JM, Lave JR, Houck PR, Coulehan JL: Treating major depression in primary
care practice. Eight-month clinical outcomes. Archives of General Psychiatry
107. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR,
Pilkonis PA, Leber WR, Docherty JP, et al: National Institute of Mental
Health Treatment of Depression Collaborative Research Program.
General effectiveness of treatments. Arch Gen Psychiatry 1989, 46:971–982.
108. O'Hara MW, Stuart S, Gorman LL, Wenzel A: Efficacy of interpersonal
psychotherapy for postpartum depression. Arch Gen Psychiatry 2000,
109. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders, Third Edition, Revised. Washington DC: American Psychiatric
110. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders (4th edition). Washington DC: American Psychiatric Association;
111. McCullough JP: Treatment for Chronic Depression. Cognitive Behavioral
Analysis System of Psychotherapy. New York: Guilford Press; 2000.
112. Beck AT, Steer RA, Brown GK: Beck Depression Inventory: Manual. San
Antonio: Harcourt Brace; 1987.
113. Padesky CA, Greenberger D: Clinician's guide to mind over mood. New York:
Guilford Press; 1995.
114. Stewart DE: Hepatic adverse reactions associated with nefazodone. Can J
Psychiatry 2002, 47:375–377.
115. Zimmerman M, Posternak MA, Chelminski I: Is it time to replace the
Hamilton Depression Rating Scale as the primary outcome measure in
treatment studies of depression? J Clin Psychopharmacol 2005, 25:105–110.
116. Bagby RM, Ryder AG, Schuller DR, Marshall MB: The Hamilton Depression
Rating Scale: has the gold standard become a lead weight? Am J
Psychiatry 2004, 161:2163–2177.
117. Santen G, Danhof M, Pasqua OD: Sensitivity of the Montgomery Asberg
Depression Rating Scale to response and its consequences for the
assessment of efficacy. J Psychiatr Res 2009, 43:1049–1056.
118. Schotte CKW, Maes M, Cluydts R, De Doncker D, Cosyns P: Construct
validity of the Beck Depression Inventory in a depressive population.
J Affect Disord 1997, 46:115–125.
119. Richter P, Werner J, Heerlein A, Kraus A, Sauer H: On the validity of the
Beck Depression Inventory. Psychopathology 1998, 31:160–168.
Cite this article as: van Hees et al.: The effectiveness of individual
interpersonal psychotherapy as a treatment for major depressive
disorder in adult outpatients: a systematic review. BMC Psychiatry 2013
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
van Hees et al. BMC Psychiatry 2013, 13:22
Page 10 of 10